Randomised phase III trials in first-line treatment of malignant pleural mesothelioma
| Trial | Year of publication | Treatment arms | OS (months) | P value |
| Vogelzang115 | 2003 | P/C vs C | 12.1 vs 9.3 | 0.020 |
| van Meerbeeck116 | 2005 | R/C vs C | 11.4 vs 8.8 | 0.048 |
| Muers117 | 2008 | ASC+ctx vs ASC | 8.5 vs 7.6 | 0.290 |
| Zalcman119 | 2015 | P/C/B vs P/C | 18.8 vs 16.1 | 0.017 |
ASC, active symptom control; B, bevcizumab; C, cisplatin; ctx, chemotherapy: OS, overall survival; P, pemetrexed; R, ralitrexed.